Appeal for access to cystic fibrosis 'superdrug'

A new drug has shown great promise in treating cystic fibrosis, but its high cost has raised fears that it may not be widely available, writes Susan Mitchell.

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
20th January, 2013
Kalydeco: the first -- and only -- approved drug to treat the underlying cause of cystic fibrosis.

It is difficult, if not impossible, to reflect the level of excitement that a blue capsule called Kalydeco elicited when it was first approved for use in the United States. Forbes dubbed it "the most important new drug of 2012" while the Food and Drug Administration (FDA) in the United States described it as a "breakthrough therapy".

Kalydeco is the first - and only - approved drug to treat the underlying cause of cystic fibrosis (CF)...

Subscribe from just €1 for the first month!


What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

The year in review

Newsround: What Thursday’s papers say